J D Nguyen1, P T Bremer2, C S Hwang2, S A Vandewater1, K C Collins2, K M Creehan1, K D Janda2, M A Taffe3. 1. Department of Neuroscience, The Scripps Research Institute, La Jolla, CA, USA. 2. Departments of Chemistry, Immunology and Microbial Science, Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA. 3. Department of Neuroscience, The Scripps Research Institute, La Jolla, CA, USA. Electronic address: mtaffe@scripps.edu.
Abstract
BACKGROUND: Immunotherapies directed against methamphetamine (MA) abuse have shown success in rodent models, however only a limited number of studies have investigated active vaccination in female mice and none in female rats. It is critical to determine if potential immunotherapeutic strategies generalize across sex, particularly for drugs that may produce significant sex-differences on behavioral or physiological endpoints. METHODS: Female Wistar rats were initially vaccinated with keyhole-limpet hemocyanin (KLH) or an anti-methamphetamine-KLH conjugate (MH6-KLH) three times over five weeks and implanted with radiotelemetry devices to assess locomotor activity and body temperature responses to MA. Rats were first exposed to MA via vapor inhalation (100mg/mL in propylene glycol) and then by injection (0.25-1.0mg/kg, i.p.) and vapor after a final vaccine boost. RESULTS: The MH6-KLH vaccine generated an increase in antibody titers across the initial 6-week, 3 immunization protocol and a restoration of titer after a week 14 booster. Locomotor stimulation induced by 0.25mg/kg MA, i.p, in the KLH group was prevented in the MH6-KLH group. MH6-KLH animals also exhibited an attenuated locomotor stimulation produced by 0.5mg/kg MA, i.p. No group differences in locomotion induced by vapor inhalation of MA were observed and body temperature was not differentially affected by MA across the groups, most likely because vapor inhalation of MA that produced similar locomotor stimulation resulted in ∼10-fold higher plasma MA levels. CONCLUSIONS: This study confirms the efficacy of the MH6-KLH vaccine in attenuating the effects of MA in female rats.
BACKGROUND: Immunotherapies directed against methamphetamine (MA) abuse have shown success in rodent models, however only a limited number of studies have investigated active vaccination in female mice and none in female rats. It is critical to determine if potential immunotherapeutic strategies generalize across sex, particularly for drugs that may produce significant sex-differences on behavioral or physiological endpoints. METHODS: Female Wistar rats were initially vaccinated with keyhole-limpet hemocyanin (KLH) or an anti-methamphetamine-KLH conjugate (MH6-KLH) three times over five weeks and implanted with radiotelemetry devices to assess locomotor activity and body temperature responses to MA. Rats were first exposed to MA via vapor inhalation (100mg/mL in propylene glycol) and then by injection (0.25-1.0mg/kg, i.p.) and vapor after a final vaccine boost. RESULTS: The MH6-KLH vaccine generated an increase in antibody titers across the initial 6-week, 3 immunization protocol and a restoration of titer after a week 14 booster. Locomotor stimulation induced by 0.25mg/kg MA, i.p, in the KLH group was prevented in the MH6-KLH group. MH6-KLH animals also exhibited an attenuated locomotor stimulation produced by 0.5mg/kg MA, i.p. No group differences in locomotion induced by vapor inhalation of MA were observed and body temperature was not differentially affected by MA across the groups, most likely because vapor inhalation of MA that produced similar locomotor stimulation resulted in ∼10-fold higher plasma MA levels. CONCLUSIONS: This study confirms the efficacy of the MH6-KLH vaccine in attenuating the effects of MA in female rats.
Authors: Shawn M Aarde; Kevin M Creehan; Sophia A Vandewater; Tobin J Dickerson; Michael A Taffe Journal: Psychopharmacology (Berl) Date: 2015-05-01 Impact factor: 4.530
Authors: Michelle L Miller; Amira Y Moreno; Shawn M Aarde; Kevin M Creehan; Sophia A Vandewater; Brittani D Vaillancourt; M Jerry Wright; Kim D Janda; Michael A Taffe Journal: Biol Psychiatry Date: 2012-10-23 Impact factor: 13.382
Authors: Jacques D Nguyen; Shawn M Aarde; Sophia A Vandewater; Yanabel Grant; David G Stouffer; Loren H Parsons; Maury Cole; Michael A Taffe Journal: Neuropharmacology Date: 2016-05-30 Impact factor: 5.250
Authors: Jacques D Nguyen; Paul T Bremer; Alex Ducime; Kevin M Creehan; Brent R Kisby; Michael A Taffe; Kim D Janda Journal: Neuropharmacology Date: 2016-12-09 Impact factor: 5.250
Authors: Colin N Haile; Therese A Kosten; Xiaoyun Y Shen; Patrick W O'Malley; Kevin J Winoske; Berma M Kinsey; Yan Wu; Zhen Huang; Ernest D Lykissa; Naga Naidu; Joseph A Cox; Reetakshi Arora; Thomas R Kosten; Frank M Orson Journal: Am J Addict Date: 2015-11-19
Authors: Christian Montanari; Leslie K Kelley; Tony M Kerr; Maury Cole; Nicholas W Gilpin Journal: Psychopharmacology (Berl) Date: 2019-11-23 Impact factor: 4.530
Authors: Mehrak Javadi-Paydar; Tony M Kerr; Eric L Harvey; Maury Cole; Michael A Taffe Journal: Drug Alcohol Depend Date: 2019-02-27 Impact factor: 4.492
Authors: Courtney M Keller; Allyson L Spence; Misty W Stevens; S Michael Owens; Glenn F Guerin; Nicholas E Goeders Journal: Psychopharmacology (Berl) Date: 2019-11-22 Impact factor: 4.530
Authors: Misty W Stevens; Daniela Rüedi-Bettschen; Melinda G Gunnell; Rachel Tawney; C Michael West; S Michael Owens Journal: Drug Alcohol Depend Date: 2019-08-30 Impact factor: 4.492
Authors: Rodell C Barrientos; Eric W Bow; Connor Whalen; Oscar B Torres; Agnieszka Sulima; Zoltan Beck; Arthur E Jacobson; Kenner C Rice; Gary R Matyas Journal: Mol Pharm Date: 2020-08-13 Impact factor: 4.939
Authors: Rodell C Barrientos; Connor Whalen; Oscar B Torres; Agnieszka Sulima; Eric W Bow; Essie Komla; Zoltan Beck; Arthur E Jacobson; Kenner C Rice; Gary R Matyas Journal: Bioconjug Chem Date: 2021-06-02 Impact factor: 4.774